Darunavir Outcomes Study: Comparative Effectiveness of Virologic Suppression, Regimen Durability, and Discontinuation Reasons for Three-Class Experienced Patients at 48 Weeks

Several new antiretroviral (ARV) agents for treatment experienced HIV-infected patients have been approved since June 2006, including darunavir (DRV) and raltegravir (RAL). While efficacious in clinical trials, the effectiveness, durability, and tolerability of these new ARVs remains understudied in...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Willig, James H., Aban, Inmaculada, Nevin, Christa R., Ye, Jiatao, Raper, James L., McKinnel, James A., DeLaitsch, Lori L., Mrus, Joseph M., De La Rosa, Guy R., Mugavero, Michael J., Saag, Michael S.
Formato: Artigo
Idioma:Inglês
Publicado em: Mary Ann Liebert, Inc. 2010
Assuntos:
Outcomes Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3011996/
https://ncbi.nlm.nih.gov/pubmed/20961276
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/aid.2010.0059
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados